NRG2

Across TCGA pan-cancer cohorts, NRG2 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated NRG2 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher NRG2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NRG2 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LUSC, LUAD, and STAD are the cancer types where NRG2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	III,IV	0.095	0.691	<.001	31	view →
LUAD	OS	Median	II,III,IV	0.131	0.712	<.001	22	view →
STAD	OS	Median	All	0.224	0.729	.007	15	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
PRAD	OS	Median	All	0.102	0.885	<.001	12	view →
READ	DFS	Median	III,IV	0.182	0.745	.007	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	All	0.396	0.193	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

NRG2–LUSC (OS)

Open the LUSC breakdown →